Abstract
The development of obesity consists of 3 distinct processes: differentiation of new adipocytes from precursor preadipocytic cells, formation of mature adipocytes, and excess accumulation of lipids in the adipocytes resulting in cell enlargement. This review aims to discuss the possible role of metallothionein (MT) in adipose tissue in the development of obesity. MT is induced in adipose tissue during the development of obesity. In addition, MT plays a preventive role against obesity in female mice. Although the detailed mechanism is presently unknown, one of the factors involved is the mesoderm-specific transcript (MEST/Peg1), adipocyte enlargement factor. MT has a potential to prevent obesity-related diseases, at least in part, through suppression of disease-induced generation of superoxide and endoplasmic reticulum stress and associated damage. Studies on the development of a MT inducer will encourage potential clinical use for obesity- related diseases.
Keywords: obesity, metallothionein, MEST/Peg1, adipocyte.
Current Pharmaceutical Biotechnology
Title:Obesity and Metallothionein
Volume: 14 Issue: 4
Author(s): Masao Sato, Takashige Kawakami, Yoshito Kadota, Maki Mori and Shinya Suzuki
Affiliation:
Keywords: obesity, metallothionein, MEST/Peg1, adipocyte.
Abstract: The development of obesity consists of 3 distinct processes: differentiation of new adipocytes from precursor preadipocytic cells, formation of mature adipocytes, and excess accumulation of lipids in the adipocytes resulting in cell enlargement. This review aims to discuss the possible role of metallothionein (MT) in adipose tissue in the development of obesity. MT is induced in adipose tissue during the development of obesity. In addition, MT plays a preventive role against obesity in female mice. Although the detailed mechanism is presently unknown, one of the factors involved is the mesoderm-specific transcript (MEST/Peg1), adipocyte enlargement factor. MT has a potential to prevent obesity-related diseases, at least in part, through suppression of disease-induced generation of superoxide and endoplasmic reticulum stress and associated damage. Studies on the development of a MT inducer will encourage potential clinical use for obesity- related diseases.
Export Options
About this article
Cite this article as:
Sato Masao, Kawakami Takashige, Kadota Yoshito, Mori Maki and Suzuki Shinya, Obesity and Metallothionein, Current Pharmaceutical Biotechnology 2013; 14 (4) . https://dx.doi.org/10.2174/1389201011314040008
DOI https://dx.doi.org/10.2174/1389201011314040008 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
25th Anniversary Special Issue.
Current Pharmaceutical Biotechnology (CPB) is celebrating its 25th anniversary with a special issue highlighting the journal’s growth and its pivotal contributions to innovation and knowledge in academia. Since its inaugural issue in 2000, CPB has fostered a multidisciplinary platform for emerging scholars to publish high-quality research in pharmaceutical biotechnology. Over ...read more
Latest Advancements in Biotherapeutics.
The scope of this thematic issue is to comprehensively explore the rapidly evolving landscape of biotherapeutics, emphasizing breakthroughs in precision medicine. Encompassing diverse therapeutic modalities, the issue will delve into the latest developments in monoclonal antibodies, CRISPR/Cas gene editing, CAR-T cell therapies, and innovative drug delivery systems, such as nanoparticle-based ...read more
Machine Learning and Artificial Intelligence for Medical Data Analysis and Human Information Analysis in Healthcare
The intersection of machine learning (ML) and artificial intelligence (AI) with the pharmaceutical industry is revolutionizing traditional paradigms in drug discovery and development. These technologies have introduced innovative approaches to analyzing complex datasets and predicting chemical properties, leading to more efficient identification and optimization of drug candidates. By employing sophisticated ...read more
Process Development of Cell & Gene Therapy.
Cell and Gene Therapy is one of the most fundamental sectors of the biopharmaceutical industry. An efficient process development not only lowers the cost of CMC manufacturing but also best guarantees the quality of the production of biologics for newer Cell and Gene Therapy modalities. Here, we provide the Special ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements